BUMETANIDE | A074700 | SANDOZ INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Hyman, Phelps & McNamara, P.C. FDA-2015-P-1103 · 4 docket documents The law firm Hyman, Phelps & McNamara, P.C. filed this citizen petition pursuant to Section 505(j)(2)(c) of the Federal Food, Drug and Cosmetic Act requesting that FDA designate Bumetanide Tablets at strengths of 0.5 mg, 1 mg, and 2 mg approved under ANDA 074225 as an additional Reference Listed Dru | 505(q) | 2015-04-08 | Withdrawn | Hyman, Phelps & McNamara, P.C. |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.1749
per ea
Lowest NADAC/Unit
$0.1109
per ea
Brand NDCs
0
Generic NDCs
6
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00185013001BUMETANIDE 2 MG TABLET | $0.1749 | EA | Generic | — | 2026-06-17 |
| 00185013005BUMETANIDE 2 MG TABLET | $0.1749 | EA | Generic | — | 2026-06-17 |
| 00185012801BUMETANIDE 0.5 MG TABLET | $0.1356 | EA | Generic | — | 2026-06-17 |
| 00185012805BUMETANIDE 0.5 MG TABLET | $0.1356 | EA | Generic | — | 2026-06-17 |
| 00185012901BUMETANIDE 1 MG TABLET | $0.1109 | EA | Generic | — | 2026-06-17 |
| 00185012905BUMETANIDE 1 MG TABLET | $0.1109 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.